Abstract 4783
Background
Many studies have suggested that dietary calcium has a protective effect on colon cancer development. The mean dietary calcium intake of Koreans is 490 mg/day, which is far less than the recommended intake of calcium 700-800mg/day. In this study, we explored the relationship between dietary calcium intake and colorectal cancer development in Koreans with relatively low calcium intake compared to Western countries.
Methods
The Health Examinees (HEXA) Study, large-scale genomic community-based prospective cohort study was designed to identify the general characteristics of major chronic disease in Korean. Participants in this analysis consisted with 135,230 participants aged 40-69 years recruited between 2004 and 2013. The calcium intake level was categories by Dietary Reference Intakes for Koreans (KDRIs). Cox proportional hazards regression model was used to estimate hazard ratio (HR) and corresponding 95% confidence intervals (CI) for colorectal cancer risk adjusting for potential confounders.
Results
Median energy-adjusted calcium intake was 385.5mg/day in men and 420.2mg/day in women. In the multivariate-adjusted model, compared with the group consumed less than the recommended intake of calcium, the group consumed more than the recommended intake of calcium showed a marginally significant reduction in the risk of colorectal cancer in women. (HR = 0.62, 95% CI: 0.38-1.02). But, among men, no significant association were observed between the dietary calcium intake and colorectal cancer risk (HR = 0.88, 95% CI: 0.56-1.37).
Conclusions
Korean women who adhere to the recommended intake of calcium showed a reduced risk of colorectal cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The National Research Foundation of Korea, No. 2017R1A2B4009233.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3059 - Intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection (IOCCRC): A randomized, multicenter, prospective, phase III trial
Presenter: Rongxin Zhang
Session: Poster Display session 2
Resources:
Abstract
3082 - Prognostic and predictive role of body mass index (BMI) in metastatic colorectal cancer (mCRC): a pooled analisys of TRIBE and TRIBE-2 studies by GONO
Presenter: Emanuela Dell'Aquila
Session: Poster Display session 2
Resources:
Abstract
3618 - Drug holidays and overall survival in patients treated for metastatic colorectal cancer
Presenter: Silvio Ken Garattini
Session: Poster Display session 2
Resources:
Abstract
6111 - Quality of life during 1st-line FOLFOXIRI+/- panitumumab in RAS wild-type metastatic colorectal cancer: Results from the randomized VOLFI trial (AIO KRK-0109)
Presenter: Michael Geissler
Session: Poster Display session 2
Resources:
Abstract
1042 - A biomarker combination indicating resistance to FOLFOX plus bevacizumab in metastastic colorectal cancer : results of phase I of the PERMAD trial
Presenter: Thomas Seufferlein
Session: Poster Display session 2
Resources:
Abstract
3291 - Microsatellite Instability (MSI) status and prognosis in colorectal cancer: meta-analysis
Presenter: James Toh
Session: Poster Display session 2
Resources:
Abstract
2046 - Choosing the right strategy based on individualized treatment effect predictions: Combination versus sequential chemotherapy in patients with metastatic colorectal cancer.
Presenter: Miriam Koopman
Session: Poster Display session 2
Resources:
Abstract
2589 - Noninferiority on overall survival of every-2-weeks vs weekly schedule of cetuximab for first-line treatment of RAS wild-type metastatic colorectal cancer
Presenter: Stefan Kasper
Session: Poster Display session 2
Resources:
Abstract
4944 - POLAF study: Efficacy and safety of FOLFIRI/aflibercept in a phase II trial in patients with metastatic colorectal cancer: Results of plasmatic prognostic and predictive markers
Presenter: Maria Elena Elez Fernandez
Session: Poster Display session 2
Resources:
Abstract
2042 - The accuracy of the clinical PCI score in patients with peritoneal carcinomatosis of colorectal cancer
Presenter: Nadine De Boer
Session: Poster Display session 2
Resources:
Abstract